Wednesday, February 10, 2010, 5:20pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Inspire Pharmaceuticals, Inc. (ISPH)

At 5:00AM SGT: 5.49 USD   0.00 (0.00%)  
 MORE ON ISPH 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Inspire Pharmaceuticals, Inc. (NGM:ISPH) Delayed quote dataEdit
Last Trade:5.49 USD
Trade Time:5:00AM SGT
Change: 0.00 (0.00%)
Prev Close:5.49
Open:N/A
Bid:N/A
Ask:N/A
1y Target Est:9.80
Day's Range:N/A - N/A
52wk Range:2.59 - 7.03
Volume:0
Avg Vol (3m):639,638
Market Cap:451.83M
P/E (ttm):N/A
EPS (ttm):-0.78
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add ISPH to Portfolio   Download Data

 HEADLINES 
•Inspire Announces Webcast of Presentation at BIO CEO Conference
Business Wire (Thu, Feb 4)
•Biotech's Latest Failed Trials, Missed Targets
at Seeking Alpha (Mon, Jan 25)
•INSPIRE PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Fri, Jan 22)
•Inspire shares fall on failed eye drug study
AP (Fri, Jan 22)
•UPDATE - Inspire Pharma eye drug fails in late-stage trial
at Reuters (Fri, Jan 22)
•Early-Market Movers: SunOpta, Sinovac Biotech
at Fox Business (Thu, Jan 21)
•Inspire dry eye treatment fails late-stage study
AP (Thu, Jan 21)
•Blockbuster, CalAmp: Early Volume Plays
at TheStreet.com (Thu, Jan 21)
•Inspire Dry Eye Drug Fails Key Test: BioBuzz
at TheStreet.com (Thu, Jan 21)
•Inspire Phase 3 trial fails to meet endpoints
at MarketWatch (Thu, Jan 21)
•Inspire Announces Results of Phase 3 PROLACRIA Trial for Dry Eye
Business Wire (Thu, Jan 21)
More Headlines for ISPH...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.70
EPS Est (in 2 years) (Dec-10) :-0.53
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices